Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients

Autor:	Timothy J. Vreeland, Alfred F. Trappey, George E. Peoples, Erika J Schneble, James T. Symanowski, Michael Papamichail, Sathibalan Ponniah, Alexandros Ardavanis, Sonia A. Perez, John S. Berry, Eric von Hofe, Guy T. Clifton, Nathan M. Shumway, Elizabeth A. Mittendorf, Ritesh Patil
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty MHC class II biology business.industry medicine.medical_treatment medicine.disease Epitope Breast cancer Internal medicine Immunology AE37 vaccine medicine biology.protein skin and connective tissue diseases business neoplasms Adjuvant
Zdroj:	Journal of Clinical Oncology. 32:638-638
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.638
Popis:	638 Background: AE37 is the Ii-Key hybrid of the HER2 peptide AE36 (HER2 aa:776-790). It is a MHC class II epitope capable of stimulating CD4+ helper T-cells. We have completed accrual to a prospec...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::61a396ab9553c40c31059699f31386a2 https://doi.org/10.1200/jco.2014.32.15_suppl.638 Zobrazit plný text záznamu